Related Experiment Video
Updated: Feb 5, 2026
05:05
Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
12.7K
Glaucoma Drugs in the Pipeline.
Paul L Kaufman1, Mary E Mohr1, Scott P Riccomini1
1University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI.
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)
|September 18, 2018
Summary
New glaucoma treatments focus on improving medication adherence and long-term intraocular pressure (IOP) control. Advances include novel drug compounds, gene therapy, and innovative delivery devices for better patient outcomes.
Area of Science:
- Ophthalmology
- Pharmacology
- Biotechnology
Background:
- Glaucoma management is challenging due to treatment resistance and poor adherence to topical eye drops.
- Maintaining optimal intraocular pressure (IOP) often requires multiple medications over time.
- Existing treatments face limitations in long-term efficacy and patient compliance.
Purpose of the Study:
- To review recent advancements in glaucoma therapeutics.
- To highlight novel compounds, delivery systems, and alternative therapies.
- To discuss the future direction of personalized glaucoma treatment.
Main Methods:
- Review of recent FDA-approved topical glaucoma medications targeting the conventional outflow pathway.
- Discussion of emerging therapies including gene therapy, stem cells, and novel drug formulations.
- Analysis of strategies for sustained IOP reduction and improved patient adherence.
Main Results:
- Recent approvals include rho kinase inhibitors and nitric oxide donating compounds targeting trabecular meshwork outflow.
- Gene therapy and stem cell strategies show promise for long-term IOP management, reducing reliance on daily drops.
- Novel formulations and devices aim for controlled, extended therapeutic delivery over months.
Conclusions:
- The future of glaucoma therapy emphasizes personalized approaches based on individual patient factors.
- Novel therapeutics offer expanded options for managing glaucoma and preserving vision.
- Innovations aim to improve treatment efficacy, adherence, and overall patient quality of life.
Related Concept Videos
01:25Glaucoma: Overview
1.4K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.4K
01:27Open Angle Glaucoma: Treatment
999
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
999
01:28Angle Closure Glaucoma: Treatment
1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K
01:25Pharmacokinetics: Drug–Drug Interactions
447
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
447
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
160
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
160
01:26FDA Approved Drugs: Changes to Approved Drugs
269
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
269